These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 19161986)

  • 21. G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in patients with thrombocytopenia or leukopenia prior to auto-SCT.
    Micallef IN; Jacobsen ED; Shaughnessy P; Gandhi PJ; Calandra G; van Rhee F; Uberti J
    Bone Marrow Transplant; 2013 Feb; 48(2):303-4. PubMed ID: 22773123
    [No Abstract]   [Full Text] [Related]  

  • 22. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
    Cashen A; Lopez S; Gao F; Calandra G; MacFarland R; Badel K; DiPersio J
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1253-61. PubMed ID: 18940680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma.
    Grignani G; Perissinotto E; Cavalloni G; Carnevale Schianca F; Aglietta M
    J Clin Oncol; 2005 Jun; 23(16):3871-2; author reply 3872-3. PubMed ID: 15923599
    [No Abstract]   [Full Text] [Related]  

  • 24. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist.
    Broxmeyer HE; Orschell CM; Clapp DW; Hangoc G; Cooper S; Plett PA; Liles WC; Li X; Graham-Evans B; Campbell TB; Calandra G; Bridger G; Dale DC; Srour EF
    J Exp Med; 2005 Apr; 201(8):1307-18. PubMed ID: 15837815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist.
    Liles WC; Rodger E; Broxmeyer HE; Dehner C; Badel K; Calandra G; Christensen J; Wood B; Price TH; Dale DC
    Transfusion; 2005 Mar; 45(3):295-300. PubMed ID: 15752146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing stem cell collection through CXCR4 antagonists.
    Mahaseth H; Kaufman J
    Front Biosci (Schol Ed); 2012 Jan; 4(2):611-9. PubMed ID: 22202080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist.
    Liles WC; Broxmeyer HE; Rodger E; Wood B; Hübel K; Cooper S; Hangoc G; Bridger GJ; Henson GW; Calandra G; Dale DC
    Blood; 2003 Oct; 102(8):2728-30. PubMed ID: 12855591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma.
    Oelschlaegel U; Bornhauser M; Boxberger S; Kroschinsky F; Illmer T; Hoelig K; Calandra G; Ehninger G; Platzbecker U
    Ann Hematol; 2007 Aug; 86(8):569-73. PubMed ID: 17437111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study.
    Fruehauf S; Veldwijk MR; Seeger T; Schubert M; Laufs S; Topaly J; Wuchter P; Dillmann F; Eckstein V; Wenz F; Goldschmidt H; Ho AD; Calandra G
    Cytotherapy; 2009; 11(8):992-1001. PubMed ID: 19929463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
    Flomenberg N; Comenzo RL; Badel K; Calandra G
    Biol Blood Marrow Transplant; 2010 May; 16(5):695-700. PubMed ID: 20067838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.
    Brave M; Farrell A; Ching Lin S; Ocheltree T; Pope Miksinski S; Lee SL; Saber H; Fourie J; Tornoe C; Booth B; Yuan W; He K; Justice R; Pazdur R
    Oncology; 2010; 78(3-4):282-8. PubMed ID: 20530974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
    Stiff P; Micallef I; McCarthy P; Magalhaes-Silverman M; Weisdorf D; Territo M; Badel K; Calandra G
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mobilization of hematopoietic stem cells into the peripheral blood.
    Damon LE; Damon LE
    Expert Rev Hematol; 2009 Dec; 2(6):717-33. PubMed ID: 21082960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
    Stewart DA; Smith C; MacFarland R; Calandra G
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100.
    Bonig H; Chudziak D; Priestley G; Papayannopoulou T
    Exp Hematol; 2009 Mar; 37(3):402-15.e1. PubMed ID: 19157683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
    Sancho JM; Duarte R; Medina L; Querol S; Marín P; Sureda A;
    Med Clin (Barc); 2016 Sep; 147(5):223.e1-223.e7. PubMed ID: 27374031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mobilisation of haematopoietic stem cells in paediatric patients, prior to autologous transplantation following administration of plerixafor and G-CSF.
    Patel B; Pearson H; Zacharoulis S
    Pediatr Blood Cancer; 2015 Aug; 62(8):1477-80. PubMed ID: 25755177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics.
    Fruehauf S; Seeger T; Maier P; Li L; Weinhardt S; Laufs S; Wagner W; Eckstein V; Bridger G; Calandra G; Wenz F; Zeller WJ; Goldschmidt H; Ho AD
    Exp Hematol; 2006 Aug; 34(8):1052-9. PubMed ID: 16863911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells.
    Dar A; Schajnovitz A; Lapid K; Kalinkovich A; Itkin T; Ludin A; Kao WM; Battista M; Tesio M; Kollet O; Cohen NN; Margalit R; Buss EC; Baleux F; Oishi S; Fujii N; Larochelle A; Dunbar CE; Broxmeyer HE; Frenette PS; Lapidot T
    Leukemia; 2011 Aug; 25(8):1286-1296. PubMed ID: 21494253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.